乳幼児のBRUE(Brief Resolved Unexplained Event)に関する最新情報:エビデンス、リスク層別化、および乳幼児のケア改善
Brit Long1, Anna M DePompolo2, Michael Gottlieb3
1Department of Emergency Medicine, University of Virginia, Charlottesville, VA, USA.
The American journal of emergency medicine
|January 10, 2026
まとめ
乳幼児の一時的な原因不明の事象(BRUE)は、しばしば良性ですが、不必要な評価につながる可能性があります。現在のエビデンスを理解することは、救急外来の臨床医が低リスクの症例をリスク層別化し、ケアを改善し、医療費を削減するのに役立ちます。
科学分野:
- 小児救急医学
- 臨床小児科学
- エビデンスに基づく医学
背景:
- 一時的な原因不明の事象(BRUE)は多くの乳幼児に影響を与え、しばしば良性の原因があります。
- 低リスクのBRUE症例は、不必要な評価や入院をしばしば受けます。
- 現在のBRUEエビデンスの認識は、救急部門(ED)の臨床医にとって極めて重要です。
研究 の 目的:
- 小児BRUEに関する主要なエビデンスに基づく最新情報を評価すること。
- BRUEを管理する救急外来の臨床医のためのガイダンスを提供すること。
主な方法:
- BRUEに関する現在のエビデンスの文献レビュー。
- 診断基準とリスク層別化アプローチの分析。
- 救急部門での遭遇に焦点を当てる。
主要な成果:
- BRUEの定義:1歳未満の乳幼児における、呼吸、筋緊張、意識、または顔色の変化を伴う、突然の(1分未満の)回復したエピソード。
- BRUEは、介護者と臨床医に大きな精神的苦痛を引き起こします。
- リスク層別化と共有意思決定が不可欠です。
結論:
- 低リスクのBRUEイベントを特定することで、不必要な検査が最小限に抑えられます。
- 非低リスク症例に対する適切な評価が不可欠です。
- 現在のBRUE文献を理解することは、小児患者の救急医療を改善します。
関連する概念動画
Pharmacokinetics in Pediatric Patients: Drug Excretion
201
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201
Pulmonary Embolism I: Introduction
492
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
492
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
298
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
298
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Cardiopulmonary Resuscitation III: AED Use
512
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
512
Pharmacokinetics in Pediatric Patients: Drug Metabolism
185
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185


